HUTCHMED (China) Limited (AIM:HCM)

Market Cap	1.98B
Revenue (ttm)	439.54M
Net Income (ttm)	340.78M
Shares Out	859.30M
EPS (ttm)	0.39
PE Ratio	5.95
Forward PE	13.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,306
Average Volume	35,453
Open	239.00
Previous Close	235.00
Day's Range	230.00 - 239.00
52-Week Range	185.50 - 336.00
Beta	0.47
RSI	45.15
Earnings Date	Nov 13, 2025

About HUTCHMED (China)

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 1,811
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: HCM

Financial Performance

In 2024, HUTCHMED (China)'s revenue was $630.20 million, a decrease of -24.80% compared to the previous year's $838.00 million. Earnings were $37.73 million, a decrease of -62.56%.

Financial numbers in USD